Zydus Lifesciences Gets USFDA Approval for Generic Cancer Treatment
Zydus Lifesciences receives USFDA approval for its generic version of Cyclophosphamide capsules, a chemotherapy drug used to treat various cancers. The drug will be manufactured in Ahmedabad, India.
New Delhi, Dec 14 (PTI) Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulatory for its generic version of cancer treatment drug Cyclophosphamide capsules.
The approval by the US Food and Drug Administration (USFDA) is for Cyclophosphamide capsules of strengths 25 mg and 50 mg, Zydus Lifesciences said in a regulatory filing.
The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India, it added.
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cells. It treats lymphoma, myeloma, leukemia, breast cancer and ovarian cancer, the company said.
Cyclophosphamide Capsules 25 mg and 50 mg had annual sales of USD 6 million in the US, Zydus Lifesciences said citing IQVIA MAT (moving annual total) October, 2023 data.
The approval by the US Food and Drug Administration (USFDA) is for Cyclophosphamide capsules of strengths 25 mg and 50 mg, Zydus Lifesciences said in a regulatory filing.
The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India, it added.
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cells. It treats lymphoma, myeloma, leukemia, breast cancer and ovarian cancer, the company said.
Cyclophosphamide Capsules 25 mg and 50 mg had annual sales of USD 6 million in the US, Zydus Lifesciences said citing IQVIA MAT (moving annual total) October, 2023 data.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 7.98 ( -1.12)
- 72031315
- G G Engineering
- 0.83 ( -4.60)
- 28985254
- Standard Capital
- 0.49 ( 0.00)
- 21559261
- Sharanam Infra
- 0.67 (+ 4.69)
- 21142271
- Alok Industries Ltd.
- 19.55 (+ 18.70)
- 17658950
MORE NEWS
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback